Status:
COMPLETED
An Open Label Study That Compares Varenicline to Transdermal Nicotine Patch for Smoking Cessation
Lead Sponsor:
Pfizer
Conditions:
Smoking Cessation
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
Open-label comparison of standard 12-week regimen of varenicline with standard 10-week regimen of transdermal nicotine patch for smoking cessation.
Eligibility Criteria
Inclusion
- Subjects must have smoked an average of at least 15 cigarettes per day during the past year and over the month prior to the screening visit, with no period of abstinence greater than 3 months in the past year.
Exclusion
- Subjects with clinically significant cardiovascular disease in the past 6 months.
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
End Date :
June 1 2006
Estimated Enrollment :
730 Patients enrolled
Trial Details
Trial ID
NCT00143325
Start Date
January 1 2005
End Date
June 1 2006
Last Update
June 4 2007
Active Locations (22)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Palo Alto, California, United States
2
Pfizer Investigational Site
Santa Ana, California, United States
3
Pfizer Investigational Site
Farmington, Connecticut, United States
4
Pfizer Investigational Site
Lexington, Kentucky, United States